NCT04250545View on ClinicalTrials.gov

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Leptomeningeal NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
DRUG

Sapanisertib

Given PO

DRUG

Telaglenastat Hydrochloride

Given PO

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

90020

Keck Medicine of USC Koreatown, Los Angeles

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

92618

City of Hope at Irvine Lennar, Irvine

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH